Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa

Archives of Neurology

Volumn 55, Issue 8, 1998, Pages 1089-1095

  Adler, Charles H ^a   Singer, Carlos ^b   O'Brien, Christopher ^c   Hauser, Robert A ^d   Lew, Mark F ^e   Marek, Kenneth L ^f   Dorflinger, Ernest ^g   Pedder, Simon ^g   Deptula, Dennis ^g   Yoo, Kisook ^g  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c Colorado Neurol Inst Movement D ^*  (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f YALE UNIVERSITY   (United States)

^g HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; SELEGILINE; TOLCAPONE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ON OFF PHENOMENON; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIPARKINSON AGENTS; BENZOPHENONES; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 17944385730     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.8.1089     Document Type: Article

References (16)

1. Zürcher G, Colzi A, Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl. 1990;32:375-380.
2. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol. 1995;40:253-262.
3. Levodopa. In: Dollery C, ed. Therapeutic Drugs. Edinburgh, Scotland: Churchill Livingstone; 1991:L10-L15.
4. Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-dopa pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol. 1995;18:333-337.
5. Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol. 1995;18:258-265.
6. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology. 1994;44:2685-2688.
7. Kurth MC, Adler CH, Saint Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology. 1997;48:81-87.
8. Myllylä VV, Jackson M, Larsen JP, Baas H, Tolcapone International Parkinson's Disease Study (TIPS) Group I. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with "wearing-off" phenomenon: a multicentre, double-blind randomized, placebo-controlled trial. Eur J Neurol. 1997;4:333-341.
9. Rajput A, Martin W, Saint-Hilaire M-H, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with "wearing-off" phenomenon: a double-blind placebo-controlled, multicenter trial. Neurology. 1997;49:1066-1071.
10. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne D, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information; 1987:153-163.
11. Bergner M, Bobbitt RA, Carter WB, Gilson SB. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981;19: 787-805.
12. Zürcher G, Dingemanse J, Da Prada M. Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G, eds. New Developments in Therapy of Parkinson's Disease. Rome, Italy: John Libbey; 1991:37-43.
13. Napolitano A, Zürcher G, Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol. 1995;273:215-221.
14. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;48:162-168.
15. Olanow CW, Fahn S, Muenter M, et al. A multicentre double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord. 1994;9:40-47.
16. Agid Y, Destee A, Durif F, Montastruc JL, Pollak P, on behalf of the French Tolcapone Study Group. Tolcapone, bromocriptine, and Parkinson's disease. Lancet. 1997;350:712-713.